<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">The 
 <italic>in vitro</italic> antiviral activity of chloroquine has been identified since the late 1960's (
 <xref rid="bib13" ref-type="bibr">Inglot, 1969</xref>; 
 <xref rid="bib19" ref-type="bibr">Miller and Lenard, 1981</xref>; 
 <xref rid="bib26" ref-type="bibr">Shimizu et al., 1972</xref>) and the growth of many different viruses can be inhibited in cell culture by both chloroquine and hydroxychloroquine, including the SARS coronavirus (
 <xref rid="bib16" ref-type="bibr">Keyaerts et al., 2004</xref>). Some evidence for activity in mice has been found for a variety of viruses, including human coronavirus OC43 (
 <xref rid="bib15" ref-type="bibr">Keyaerts et al., 2009</xref>), enterovirus EV-A71 (
 <xref rid="bib27" ref-type="bibr">Tan et al., 2018</xref>), Zika virus (
 <xref rid="bib17" ref-type="bibr">Li et al., 2017</xref>) and influenza A H5N1 (
 <xref rid="bib31" ref-type="bibr">Yan et al., 2013</xref>). However, chloroquine did not prevent influenza infection in a randomized, double-blind, placebo-controlled clinical trial (
 <xref rid="bib21" ref-type="bibr">Paton et al., 2011</xref>), and had no effect on dengue-infecteds patient in a randomized controlled trial in Vietnam (
 <xref rid="bib28" ref-type="bibr">Tricou et al., 2010</xref>). Chloroquine was also active 
 <italic>ex vivo</italic> but not 
 <italic>in vivo</italic> in the case of ebolavirus in mice (
 <xref rid="bib8" ref-type="bibr">Dowall et al., 2015</xref>; 
 <xref rid="bib9" ref-type="bibr">Falzarano et al., 2015</xref>), Nipah (
 <xref rid="bib20" ref-type="bibr">Pallister et al., 2009</xref>) and influenza virus (
 <xref rid="bib29" ref-type="bibr">Vigerust and McCullers, 2007</xref>) in ferrets.
</p>
